Induction of tubulin by Docetaxel is associated with p53 status in human non small cell lung cancer cell lines

Jinghua Tsai Chang, Gee Chen Chang, Jiunn Liang Ko, Hung Y. Liao, Hsin J. Liu, Chien Chih Chen, Jang Ming Su, Huei Lee, Gwo Tarng Sheu

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Docetaxel (DOC), a member of the taxane family of anticancer drugs, binds to tubulin and produces unnaturally stable microtubules that induce cell death. DOC is used clinically alone or in combination with other compounds to treat advanced stages of cancer. We have treated the human lung cancer cell lines A549 and H1299 and human cervical cancer HeLa cells with low concentrations of DOC to characterize the response of β-tubulin isotypes and p53 genes. The relationship between p53 function and DOC, acting through a microtubule-based mechanism, was examined. We found that after 18-hr treatment with DOC, β-tubulin gene transcription was enhanced in p53-null H1299 cells but not in A549 cells. Also, p53 RNA was strongly induced in the A549 cells. In addition, β-tubulin levels also increased in the H1299 cells after the DOC treatment. Further demonstrating an association of DOC treatment with p53 and β-tubulin, inhibition of p53 expression by interference RNA in A549 cells showed increasing β-tubulin gene expression with DOC treatment. We also selected a clone from the H1299 cells that stably expressed p53, examined the β-tubulin expression after DOC treatment and found an inhibition of β-tubulin induction in these p53-expressing cells. Our data suggest that the initial response of cells to DOC treatment involves p53; alternatively, in the absence of p53, tubulins may be transactivated. Selection of the DOC-resistant A549 cells showed β-tubulin expression was increased, in contrast to the initial response to the DOC treatment. From the initial and selection responses of β-tubulin in cancer cells, it appears that there is a p53-associated β-tubulin expression as a result of the DOC treatment.

Original languageEnglish
Pages (from-to)317-325
Number of pages9
JournalInternational Journal of Cancer
Volume118
Issue number2
DOIs
Publication statusPublished - Jan 15 2006
Externally publishedYes

Fingerprint

docetaxel
Tubulin
Non-Small Cell Lung Carcinoma
Cell Line
Microtubules

Keywords

  • β-tubulins
  • Docetaxel
  • Drug resistance
  • p53

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Chang, J. T., Chang, G. C., Ko, J. L., Liao, H. Y., Liu, H. J., Chen, C. C., ... Sheu, G. T. (2006). Induction of tubulin by Docetaxel is associated with p53 status in human non small cell lung cancer cell lines. International Journal of Cancer, 118(2), 317-325. https://doi.org/10.1002/ijc.21372

Induction of tubulin by Docetaxel is associated with p53 status in human non small cell lung cancer cell lines. / Chang, Jinghua Tsai; Chang, Gee Chen; Ko, Jiunn Liang; Liao, Hung Y.; Liu, Hsin J.; Chen, Chien Chih; Su, Jang Ming; Lee, Huei; Sheu, Gwo Tarng.

In: International Journal of Cancer, Vol. 118, No. 2, 15.01.2006, p. 317-325.

Research output: Contribution to journalArticle

Chang, JT, Chang, GC, Ko, JL, Liao, HY, Liu, HJ, Chen, CC, Su, JM, Lee, H & Sheu, GT 2006, 'Induction of tubulin by Docetaxel is associated with p53 status in human non small cell lung cancer cell lines', International Journal of Cancer, vol. 118, no. 2, pp. 317-325. https://doi.org/10.1002/ijc.21372
Chang, Jinghua Tsai ; Chang, Gee Chen ; Ko, Jiunn Liang ; Liao, Hung Y. ; Liu, Hsin J. ; Chen, Chien Chih ; Su, Jang Ming ; Lee, Huei ; Sheu, Gwo Tarng. / Induction of tubulin by Docetaxel is associated with p53 status in human non small cell lung cancer cell lines. In: International Journal of Cancer. 2006 ; Vol. 118, No. 2. pp. 317-325.
@article{f90f473174de442bbce6b9e319e6432c,
title = "Induction of tubulin by Docetaxel is associated with p53 status in human non small cell lung cancer cell lines",
abstract = "Docetaxel (DOC), a member of the taxane family of anticancer drugs, binds to tubulin and produces unnaturally stable microtubules that induce cell death. DOC is used clinically alone or in combination with other compounds to treat advanced stages of cancer. We have treated the human lung cancer cell lines A549 and H1299 and human cervical cancer HeLa cells with low concentrations of DOC to characterize the response of β-tubulin isotypes and p53 genes. The relationship between p53 function and DOC, acting through a microtubule-based mechanism, was examined. We found that after 18-hr treatment with DOC, β-tubulin gene transcription was enhanced in p53-null H1299 cells but not in A549 cells. Also, p53 RNA was strongly induced in the A549 cells. In addition, β-tubulin levels also increased in the H1299 cells after the DOC treatment. Further demonstrating an association of DOC treatment with p53 and β-tubulin, inhibition of p53 expression by interference RNA in A549 cells showed increasing β-tubulin gene expression with DOC treatment. We also selected a clone from the H1299 cells that stably expressed p53, examined the β-tubulin expression after DOC treatment and found an inhibition of β-tubulin induction in these p53-expressing cells. Our data suggest that the initial response of cells to DOC treatment involves p53; alternatively, in the absence of p53, tubulins may be transactivated. Selection of the DOC-resistant A549 cells showed β-tubulin expression was increased, in contrast to the initial response to the DOC treatment. From the initial and selection responses of β-tubulin in cancer cells, it appears that there is a p53-associated β-tubulin expression as a result of the DOC treatment.",
keywords = "β-tubulins, Docetaxel, Drug resistance, p53",
author = "Chang, {Jinghua Tsai} and Chang, {Gee Chen} and Ko, {Jiunn Liang} and Liao, {Hung Y.} and Liu, {Hsin J.} and Chen, {Chien Chih} and Su, {Jang Ming} and Huei Lee and Sheu, {Gwo Tarng}",
year = "2006",
month = "1",
day = "15",
doi = "10.1002/ijc.21372",
language = "English",
volume = "118",
pages = "317--325",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Induction of tubulin by Docetaxel is associated with p53 status in human non small cell lung cancer cell lines

AU - Chang, Jinghua Tsai

AU - Chang, Gee Chen

AU - Ko, Jiunn Liang

AU - Liao, Hung Y.

AU - Liu, Hsin J.

AU - Chen, Chien Chih

AU - Su, Jang Ming

AU - Lee, Huei

AU - Sheu, Gwo Tarng

PY - 2006/1/15

Y1 - 2006/1/15

N2 - Docetaxel (DOC), a member of the taxane family of anticancer drugs, binds to tubulin and produces unnaturally stable microtubules that induce cell death. DOC is used clinically alone or in combination with other compounds to treat advanced stages of cancer. We have treated the human lung cancer cell lines A549 and H1299 and human cervical cancer HeLa cells with low concentrations of DOC to characterize the response of β-tubulin isotypes and p53 genes. The relationship between p53 function and DOC, acting through a microtubule-based mechanism, was examined. We found that after 18-hr treatment with DOC, β-tubulin gene transcription was enhanced in p53-null H1299 cells but not in A549 cells. Also, p53 RNA was strongly induced in the A549 cells. In addition, β-tubulin levels also increased in the H1299 cells after the DOC treatment. Further demonstrating an association of DOC treatment with p53 and β-tubulin, inhibition of p53 expression by interference RNA in A549 cells showed increasing β-tubulin gene expression with DOC treatment. We also selected a clone from the H1299 cells that stably expressed p53, examined the β-tubulin expression after DOC treatment and found an inhibition of β-tubulin induction in these p53-expressing cells. Our data suggest that the initial response of cells to DOC treatment involves p53; alternatively, in the absence of p53, tubulins may be transactivated. Selection of the DOC-resistant A549 cells showed β-tubulin expression was increased, in contrast to the initial response to the DOC treatment. From the initial and selection responses of β-tubulin in cancer cells, it appears that there is a p53-associated β-tubulin expression as a result of the DOC treatment.

AB - Docetaxel (DOC), a member of the taxane family of anticancer drugs, binds to tubulin and produces unnaturally stable microtubules that induce cell death. DOC is used clinically alone or in combination with other compounds to treat advanced stages of cancer. We have treated the human lung cancer cell lines A549 and H1299 and human cervical cancer HeLa cells with low concentrations of DOC to characterize the response of β-tubulin isotypes and p53 genes. The relationship between p53 function and DOC, acting through a microtubule-based mechanism, was examined. We found that after 18-hr treatment with DOC, β-tubulin gene transcription was enhanced in p53-null H1299 cells but not in A549 cells. Also, p53 RNA was strongly induced in the A549 cells. In addition, β-tubulin levels also increased in the H1299 cells after the DOC treatment. Further demonstrating an association of DOC treatment with p53 and β-tubulin, inhibition of p53 expression by interference RNA in A549 cells showed increasing β-tubulin gene expression with DOC treatment. We also selected a clone from the H1299 cells that stably expressed p53, examined the β-tubulin expression after DOC treatment and found an inhibition of β-tubulin induction in these p53-expressing cells. Our data suggest that the initial response of cells to DOC treatment involves p53; alternatively, in the absence of p53, tubulins may be transactivated. Selection of the DOC-resistant A549 cells showed β-tubulin expression was increased, in contrast to the initial response to the DOC treatment. From the initial and selection responses of β-tubulin in cancer cells, it appears that there is a p53-associated β-tubulin expression as a result of the DOC treatment.

KW - β-tubulins

KW - Docetaxel

KW - Drug resistance

KW - p53

UR - http://www.scopus.com/inward/record.url?scp=28844483319&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28844483319&partnerID=8YFLogxK

U2 - 10.1002/ijc.21372

DO - 10.1002/ijc.21372

M3 - Article

VL - 118

SP - 317

EP - 325

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 2

ER -